Target intelligence / Profile preview

Ring finger and CCCH-type domains 2 (RC3H2)

Target
RC3H2
Molecular classification
RNA-binding protein, E3 ubiquitin ligase, Zinc finger protein, Post-transcriptional regulator, Other (contains RING and CCCH-type zinc finger domains)
01

Overview

Ring finger and CCCH-type domains 2 (RC3H2), also known as Roquin-2, is a highly conserved multi-domain protein. It features a RING finger domain conferring E3 ubiquitin ligase activity and a CCCH-type zinc finger domain that, together with a unique ROQ domain, mediates specific RNA binding. RC3H2 binds to conserved stem-loop motifs (constitutive decay elements or CDEs) in target mRNA 3'-untranslated regions, promoting deadenylation and degradation of these transcripts in a miRNA-independent manner. It plays a critical role in immune regulation by repressing the expression of key genes involved in T cell activation and inflammation (such as ICOS, TNFRSF4, TNF, and NFKBID), thus maintaining immunological self-tolerance and preventing hyperinflammatory states. RC3H2 acts as an E3 ubiquitin ligase, interacting with several E2 enzymes to assemble polyubiquitin chains and regulate substrate turnover. Dysfunction of RC3H2 or its paralog Roquin-1 is associated with autoimmunity, chronic inflammation, and potentially tumorigenesis. No clinically approved drugs are known to directly target RC3H2 as of the current knowledge. However, its central role in post-transcriptional gene regulation and immune homeostasis make it of interest as a potential therapeutic target for immune-related and inflammatory diseases.

Other names
Roquin-2MNABRNF164Membrane-associated nucleic acid-binding proteinRING finger and CCCH-type zinc finger domain-containing protein 2RING finger protein 164RING-type E3 ubiquitin transferase Roquin-2membrane-associated DNA binding proteinmembrane-associated nucleic acid-binding proteinring finger and CCCH-type zinc finger domains 2
02

Mechanism of action

Small molecules or biologics (in theory) that modulate RNA binding or E3 ligase activity could alter mRNA degradation pathways or immune responses

03

Biological functions

mRNA degradationRNA bindingUbiquitin-mediated protein ubiquitinationRegulation of immune responseControl of inflammationRegulation of T cell function
04

Disease associations

InflammationAutoimmunityCancer (e.g., squamous cell carcinoma of head and neck)
05

Safety considerations

Potential for immune dysregulation (autoimmunity, excess inflammation) if function is excessively modulated or lost
06

Biomarkers

RC3H2 expression has not been firmly established as a clinical biomarker, but its dysfunction is associated with autoimmune and inflammatory diseases

Beyond the preview

Go deeper on Ring finger and CCCH-type domains 2 (RC3H2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ring finger and CCCH-type domains 2 (RC3H2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call